Viatris Inc.VTRS

Is VTRS cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$16.88-0.06 (-0.35%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$20B
Large-cap
-6%
2016 — today
10-Year Price
-59%
2016 — today
52-Week Range
$9.49$17.86
Current $16.88· 88%

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Featured in rankings

Rankings recomputed after each US market close — see where VTRS stands against peers.

Similar companies

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
-46.9
N/A
Not meaningful — company is unprofitable
Sector median 25.6below sector
P/B ratio
1.4
Historically pricey
Historically pricey — last 10 years
Sector median 2.6below sector
EV / EBITDA
12.3
Historically pricey
Historically pricey — last 10 years
Sector median 15.8below sector
Dividend Yield
2.8%
Historically low
Historically low relative to the last 10 years
Sector median 1.7%above sector
FCF Yield
9.5%
Historically low
Historically low relative to the last 10 years
Sector median -9.4%above sector
Free · No credit card needed

Get alerted when VTRS is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.